R
Roberto Labianca
Researcher at Mario Negri Institute for Pharmacological Research
Publications - 271
Citations - 23600
Roberto Labianca is an academic researcher from Mario Negri Institute for Pharmacological Research. The author has contributed to research in topics: Colorectal cancer & Cancer. The author has an hindex of 64, co-authored 263 publications receiving 21387 citations.
Papers
More filters
Journal ArticleDOI
Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
Daniel J. Sargent,Silvia Marsoni,Geneviève Monges,Stephen N. Thibodeau,Roberto Labianca,Stanley R. Hamilton,Amy J. French,Brian Kabat,Nathan R. Foster,Valter Torri,Christine Ribic,Axel Grothey,Malcolm J. Moore,Alberto Zaniboni,Jean Francois Seitz,Frank A. Sinicrope,Steven Gallinger +16 more
TL;DR: Data support MMR status assessment for patients being considered for FU therapy alone and consideration of MMR status in treatment decision making and patient stratification by MMR status may provide a more tailored approach to colon cancer adjuvant therapy.
Journal ArticleDOI
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
H.-J. Schmoll,E. Van Cutsem,Alexander Stein,Vincenzo Valentini,Bengt Glimelius,Bengt Glimelius,Karin Haustermans,Bernard Nordlinger,C.J.H. van de Velde,Judith Balmaña,Jaroslaw Regula,Iris D. Nagtegaal,Regina G. H. Beets-Tan,D Arnold,Fortunato Ciardiello,Paulo M. Hoff,David J. Kerr,C.-H. Köhne,Roberto Labianca,Timothy J. Price,Werner Scheithauer,Alberto Sobrero,Josep Tabernero,Dan Aderka,S Barroso,György Bodoky,J.-Y. Douillard,H El Ghazaly,Jorge Gallardo,August Garin,Rob Glynne-Jones,Karin Jordan,A Meshcheryakov,D Papamichail,Per Pfeiffer,Ioannis Souglakos,Serdar Turhal,Andrés Cervantes +37 more
TL;DR: This ESMO guideline is recommended to be used as the basis for treatment and management decisions, delivering a clear proposal for diagnostic and treatment measures in each stage of rectal and colon cancer and the individual clinical situations.
Journal ArticleDOI
Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.
Arnaud Roth,Sabine Tejpar,Mauro Delorenzi,Pu Yan,Roberto Fiocca,Dirk Klingbiel,Daniel Dietrich,Bart Biesmans,György Bodoky,Carlo Barone,Enrique Aranda,Bernard Nordlinger,Laura Cisar,Roberto Labianca,David Cunningham,Eric Van Cutsem,Fred T. Bosman +16 more
TL;DR: In stage II-III colon cancer, the KRAS mutation status does not have major prognostic value, but BRAF is prognostic for OS in MS-L/S tumors.
Journal ArticleDOI
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
Philippe Rougier,Eric Van Cutsem,Emilio Bajetta,Norbert Niederle,Kurt Possinger,Roberto Labianca,Matilde Navarro,Rudolf Morant,Harry Bleiberg,Jacques Wils,Lucile Awad,Patrice Herait,Christian Jacques +12 more
TL;DR: Compared with fluorouracil by continuous infusion second-line irinotecan significantly improved survival in patients with advanced colorectal cancer.
Journal ArticleDOI
Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
Sharlene Gill,Charles L. Loprinzi,Daniel J. Sargent,Stephan D. Thomé,Steven R. Alberts,Daniel G. Haller,Jacqueline Benedetti,Guido Francini,Lois E. Shepherd,Jean Francois Seitz,Roberto Labianca,Wei Chen,Stephen S. Cha,Michael P. Heldebrant,Richard M. Goldberg +14 more
TL;DR: Patients with high-risk resected colon cancer obtain benefit from FU-based therapy across subsets of age, sex, location, T stage, nodal status, and grade, which may improve patients' and physicians' understanding of the potential benefits of adjuvant therapy.